Disease · MONDO_0010602
Trials173
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 76 more are not shown, since the checks do not confirm them.
1 to 20 of 173
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00984126 | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 | Phase 3 | 214 | 2017-07-27 | Congenital Bleeding Disorder, Haemophilia A | TUROCTOCOG ALFA | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00884390 | Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings | Phase 4 | 208 | 2014-09-01 | Hemophilia A | MOROCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01480180 | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A | Phase 3 | 186 | 2020-04-20 | Congenital Bleeding Disorder, Haemophilia A | TUROCTOCOG ALFA PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT01486927 | An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A | Phase 2/3 | 175 | 2016-08-09 | Hemophilia A | LONOCTOCOG ALFA, OCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01181128 | Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A | Phase 3 | 165 | 2014-08-29 | Severe Hemophilia A | OCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT03528551 | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A | Phase 3 | 160 | 2021-11-26 | Congenital Bleeding Disorder, Haemophilia A | TUROCTOCOG ALFA PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT04161495 | A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A | Phase 3 | 159 | 2023-05-24 | Factor VIII Deficiency | EFANESOCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT00840086 | Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects | Phase 3 | 150 | 2014-09-04 | Congenital Bleeding Disorder, Haemophilia A | TUROCTOCOG ALFA | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03370913 | Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) | Phase 3 | 144 | 2023-11-28 | Hemophilia A | VALOCTOCOGENE ROXAPARVOVEC | Its record names the disease | ClinicalTrials.gov |
| NCT02585960 | BAX 855 PK-guided Dosing | Phase 3 | 135 | 2019-08-26 | Hemophilia A | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Its record names the disease | ClinicalTrials.gov |
| NCT03169972 | ADYNOVATE Drug Use-Results Survey | 135 | 2025-02-04 | Hemophilia A | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Its record names the disease | ClinicalTrials.gov | |
| NCT02137850 | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A | Phase 3 | 124 | 2024-10-31 | Congenital Bleeding Disorder, Haemophilia A | TUROCTOCOG ALFA PEGOL | Its record names the disease | ClinicalTrials.gov |
| NCT02615691 | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A | Phase 3 | 120 | 2025-07-28 | Hemophilia A | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Its record names the disease | ClinicalTrials.gov |
| NCT03417245 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors | Phase 3 | 120 | 2022-02-04 | Hemophilia A, Hemophilia B | FITUSIRAN | Its record names the disease | ClinicalTrials.gov |
| NCT00703911 | Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors | 102 | 2011-12-19 | Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors | EPTACOG ALFA (ACTIVATED) | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01311648 | BAY81-8973 Pediatric Safety and Efficacy Trial | Phase 3 | 94 | 2020-11-03 | Haemophilia A | OCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT02795767 | A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors | Phase 3 | 88 | 2019-04-10 | Hemophilia A | EMICIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02492984 | PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A | Phase 4 | 85 | 2017-04-04 | Hemophilia A | MOROCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT00623480 | Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment | Phase 3 | 84 | 2013-08-07 | Hemophilia A | OCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT02093897 | Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A | Phase 3 | 84 | 2017-01-27 | Congenital Hemophilia A | LONOCTOCOG ALFA | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010602/trials